Switzerland-based pharmaceutical company,
) recently announced positive phase II data on its pipeline
candidate, LCZ696, from the PARAMOUNT study.
The study showed significant reduction in a key indicator of
morbidity and mortality in patients suffering from chronic heart
failure with preserved ejection fraction (HF-PEF).
Data from the phase II PARAMOUNT study showed that LCZ696
achieved its primary endpoint. After 12 weeks of treatment with
LCZ696, there was a reduction of more than 23% in the stress maker
NT-proBNP, compared to treatment with Diovan (valsartan).
The study also revealed that treatment with LCZ696 helped in the
reduction of the left atrial size in patients after 36 weeks.
Novartis reported that LCZ696 was well tolerated.
Novartis is currently studying LCZ696 in a phase III trial,
PARADIGM-HF for the treatment of heart failure with reduced
ejection fraction (HF-REF). Data from an earlier phase II trial
evaluating LCZ696 showed significant reduction in blood pressure
versus Diovan. Another phase III trial for the first-line treatment
of hypertension has been launched in Asia.
Already approved hypertension treatments include
Takeda Pharmaceutical Company Limited
) Edarbi and
Merck & Co
We are pleased with Novartis' wide range of products. We also
note that there is no currently approved medication for the
reduction of morbidity and mortality in HF-PEF patients. Up to half
of the 20 million Europeans and Americans afflicted by heart
failure are also suffering from this difficult-to-treat
Currently, we have a Neutral recommendation on Novartis. The
company carries a Zacks #3 Rank ("Hold" rating) in the short
MERCK & CO INC (MRK): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
(TKPYY): ETF Research Reports
To read this article on Zacks.com click here.